Noble Financial Predicts Nutriband FY2025 Earnings

Nutriband Inc. (NASDAQ:NTRB) – Analysts at Noble Financial issued their FY2025 earnings estimates for shares of Nutriband in a research report issued to clients and investors on Wednesday, January 22nd. Noble Financial analyst R. Leboyer expects that the company will post earnings per share of ($0.60) for the year. Noble Financial has a “Outperform” rating and a $13.00 price objective on the stock. Noble Financial also issued estimates for Nutriband’s Q4 2025 earnings at ($0.12) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.56) EPS, FY2027 earnings at $1.45 EPS and FY2028 earnings at $3.66 EPS.

Nutriband (NASDAQ:NTRB) last announced its quarterly earnings data on Tuesday, December 3rd. The company reported ($0.12) EPS for the quarter. Nutriband had a negative net margin of 338.51% and a negative return on equity of 54.49%.

Nutriband Price Performance

Shares of Nutriband stock opened at $8.53 on Friday. The company has a market capitalization of $94.77 million, a price-to-earnings ratio of -12.01 and a beta of 0.99. The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.01. The stock’s 50-day simple moving average is $4.66 and its 200-day simple moving average is $5.46. Nutriband has a 52 week low of $2.22 and a 52 week high of $11.78.

Nutriband Company Profile

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.